Microsort, the highly-anticipated sperm sorting technique, used for gender selection, was not approved for clinical use by the Food and Drug Administration (FDA). Therefore, for the foreseeable future the United States will have no effective sperm sorting technique available for gender selection clinical use.
This sex selection technique, developed by the Genetics and IVF Center in Virginia, allowed for the sorting of X-bearing sperm from the Y-bearing sperm prior to fertilization with a female egg. Through this sorting process patients were able to choose for a female with approximately 90 percent accuracy, and for a male sex with approximately 85 percent accuracy.
While undergoing a clinical trial, in which CHR participated, Microsort was offered in the US for elective (social) sex selection. After this clinical trial was completed, the method was still offered on a clinic trial basis for couples attempting to prevent sex-linked disease in their children. With the recent FDA decision, however, this utilization of Microsort will also terminate by the end of this month.
Gender Selection at the CHR
While sperm sorting with Microsort was effective in improving the chances of having children of a desired sex, the method was never as accurate as sex selection through in vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD). This method of sex selection will remain available to qualified patients of CHR, and nearly 100 percent accurate.
For more information about PGD please refer to the gender selection section of our website.